Pehub.com -- Trius Therapeutics Inc., a San Diego-based developer of antibacterial drugs, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol TSRX, with Credit Suisse serving as lead underwriter.